Related Experiment Video
Updated: Apr 28, 2026
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Cardiovascular risk assessment before and after kidney transplantation
Daniel Glicklich1, Parag Vohra
1From the *Department of Medicine, Division of Nephrology, New York Medical College, Valhalla, NY; and †Westchester Medical Center, Kidney Transplant Service, Valhalla, NY.
Insights
Cardiovascular disease (CVD) is a major concern for dialysis and kidney transplant patients. Kidney transplantation significantly improves survival by reducing CVD incidence and severity, highlighting the importance of cardiovascular assessment and management.
Area of Science:
- Nephrology
- Cardiology
- Transplantation Medicine
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in dialysis patients and a leading cause of death and graft loss in kidney transplant recipients.
- End-stage renal disease (ESRD) significantly elevates the risk of various cardiovascular conditions, including coronary artery disease, stroke, heart failure, and arrhythmias.
- Most ESRD patients present with multiple CVD risk factors, exacerbating their cardiovascular burden.
Purpose of the Study:
- To review the impact of kidney transplantation on cardiovascular disease in ESRD patients.
- To outline current recommendations for cardiovascular assessment and management in kidney transplant candidates and recipients.
- To identify areas for future research in CVD diagnosis and treatment within this population.
Main Methods:
- Literature review and synthesis of current evidence regarding CVD in ESRD, dialysis, and kidney transplantation.
- Analysis of the benefits of kidney transplantation on CVD outcomes.
- Summary of guidelines for cardiovascular screening and risk factor management in transplant candidates.
Main Results:
- Kidney transplantation is the preferred treatment for ESRD, substantially improving longevity and quality of life by mitigating CVD.
- Cardiovascular assessment, including echocardiography and stress testing, is crucial for transplant candidates, with higher-risk individuals requiring regular re-evaluation.
- Individualized management of CVD risk factors (hypertension, diabetes, hyperlipidemia, obesity) and consideration of statin therapy are recommended.
Conclusions:
- Successful kidney transplantation significantly reduces CVD incidence and severity in ESRD patients, primarily through correction of the uremic state and improved GFR.
- Systematic cardiovascular assessment and tailored risk factor management are essential for optimizing outcomes in kidney transplant candidates and recipients.
- Further randomized controlled trials are necessary to establish optimal diagnostic and therapeutic strategies for CVD in this vulnerable population.
Abstract:
Cardiovascular disease (CVD) is the leading cause of death in dialysis patients and the most common cause of death and allograft loss among kidney transplant recipients. End-stage renal disease (ESRD) is associated with an increased incidence and prevalence of a wide range of CVDs including coronary artery disease, stroke, congestive heart failure, atrial fibrillation, sudden cardiac death, pulmonary hypertension, and valvular heart disease. CVD risk factors are very common in patients with ESRD, and most patients have multiple risk factors. Kidney transplantation is the treatment of choice for patients with ESRD, as a successful transplant improves longevity and quality of life, primarily by decreasing the incidence and severity of CVD. Correction of the uremic state and improved glomerular filtration rate seem to be the major mechanism of this benefit. Transplant candidates should undergo cardiovascular assessment, usually echocardiography and exercise stress testing, and may require formal cardiology consultation. Higher risk candidates, including those aged >50 years, hypertension, diabetes, established coronary artery disease or peripheral vascular disease, left ventricular hypertrophy, and dialysis duration >1 year, should have repeat cardiovascular assessment every 1-2 years. Transplant candidates and recipients should have individualized treatment for CVD and risk factors such as hypertension, diabetes, hyperlipidemia, and obesity. Special consideration should be given for statin therapy, as its use is associated with decreased cardiovascular death in dialysis and transplant patients. Prospective randomized, controlled trials are needed to determine the optimal approach to diagnosis and treat CVD in the transplant candidate and recipient population.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:25Chronic Kidney Disease I: Introduction